|
|||||
![]() |
|
Life sciences tools company Agilent Technologies (NYSE:A) fell short of the market’s revenue expectations in Q1 CY2025, but sales rose 6% year on year to $1.67 billion. Its non-GAAP EPS of $1.31 per share was 3.6% above analysts’ consensus estimates.
Is now the time to buy A? Find out in our full research report (it’s free).
Agilent’s second quarter results reflected broad-based growth across most end markets and geographies, with particular strength in China, India, and environmental testing. CEO Padraig McDonnell attributed the 6% year-on-year revenue growth to stable demand for core instruments, continued recovery in the biopharma segment, and robust performance in pathology and PFAS (per- and polyfluoroalkyl substances) testing. Management also highlighted progress in its digital ecosystem, noting a 12% increase in digital orders, and pointed to operational changes—including the Ignite transformation initiative—that drove early wins in pricing and procurement. While most end markets performed as expected, academia and government remained soft, and management described the macroeconomic and geopolitical environment as “highly dynamic,” underscoring ongoing uncertainty.
Looking forward, Agilent’s guidance is shaped by ongoing tariff risks, a cautious approach to macroeconomic uncertainty, and confidence in its operational initiatives. Management maintained its full-year core growth and adjusted EPS outlook, citing the ability to offset incremental tariff costs through supply chain adjustments, pricing, and Ignite-driven efficiencies. CFO Bob McMahon noted, “A combination of supply chain moves, surcharges, and savings will allow us to fully mitigate tariff costs by next year.” The company expects continued momentum in PFAS testing, accelerating growth in its CDMO (contract development and manufacturing organization) segment, and further gains from newly launched products such as the Infinity III LC system and Seahorse XF Flex analyzer. However, management cautioned that near-term growth may be uneven given the dynamic external environment and timing of customer orders.
Management pointed to diverse geographic and product performance, with China and environmental testing outpacing expectations, while transformative operational initiatives helped offset mounting tariff pressures.
Agilent’s outlook for the coming quarters hinges on successful tariff mitigation, continued product innovation, and steady demand in core end markets, balanced against macroeconomic uncertainty.
In the coming quarters, the StockStory team will watch for (1) sustained momentum in PFAS testing and CDMO segment order growth, (2) evidence that Ignite-driven cost savings and pricing actions are offsetting tariff impacts and supporting margin stability, and (3) the pace of customer adoption for new instruments like the Infinity III LC system. Progress in these areas will be key to tracking Agilent’s ability to navigate external headwinds and deliver on its operational commitments.
Agilent currently trades at a forward P/E ratio of 19.1×. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).
The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
May-30 | |
May-29 | |
May-29 | |
May-29 | |
May-29 | |
May-29 | |
May-29 | |
May-28 | |
May-28 | |
May-28 | |
May-28 | |
May-28 | |
May-28 | |
May-28 | |
May-28 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite